Australian Health Manufacturers And Development Association Inc.

Ahmada News

go to link Recent News April 2016 come guadagnare sold con un euroi PBS listing for Leukaemia drug

LANE Cove-based pharmaceutical company Phebra, has welcomed the listing on the Australian Pharmaceutical Benefits Scheme (PBS).of its PHENASEN® (arsenic trioxide) Injection for the first line treatment of newly-diagnosed acute promyelocytic leukaemia (APL).

APL is a subtype of acute myeloid leukaemia (AML) and although it is a rare disease, with an incidence rate of approximately 2-3 patients in every 1,000,000 people this treatment provides a very good result for patients

Phebra’s Chief Executive Officer, Dr Mal Eutick, described the Federal Government’s recent decision to subsidise PHENASEN® as an excellent outcome, saying it will provide newly-diagnosed sufferers with access to this effective treatment for APL.

“Previously we had PBS reimbursement for treatment of relapsed / refractory disease however with the marketing approval in late 2015 for treatment of newly diagnosed patients and now the re-imbursement of this treatment, it’s a successful result for patients, hospitals and clinicians as well as the Company,” Dr Eutick said.

“PHENASEN® is a good example of targeted and effective cancer therapy.”

Dr Eutick said PHENASEN® has been developed by Phebra, in collaboration with leading Australian haematologists, and this injection is being manufactured by Phebra at its new manufacturing facility at Lane Cove West in Sydney.

“This outcome came from an Australian clinical trial run by the Australasian Leukaemia and Lymphoma Group (ALLG) which demonstrated that PHENASEN®, in combination with ATRA and chemotherapy, was a very effective therapy in the treatment of newly diagnosed APL patients. A European clinical trial group also observed similar outcomes,” Dr Eutick said.

“Phebra is the first pharmaceutical company to pursue and achieve registration of arsenic trioxide injection for the treatment of patients with newly diagnosed disease and we are pleased that this was trialled here in Australia and that we have received approval for this use also as an  Australian first.”

The PBS listing for PHENASEN® is effective from Friday, April 1, 2016.

The Therapeutic Goods Administration (TGA) granted marketing approval for PHENASEN® in Australia in September, 2015.

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

From the Northern Sydney Business Access



cheap flights lyrics February 2016

follow url Phebra Announces Clinical Trials for Irukandji Syndrome

Our founding member, Phebra, has announced its support for a new clinical trial to test the efficacy of Magnesium Sulphate as an antidote for Irukandji Syndrome (IS), the acute pain caused by certain jellyfish stings.

Link to the article is available here


Image from:


enter August 2015 The Review of Medicines and Medical Devices Regulation First Report Stakeholder Forums 5th and 6th of August 2015

Our Vice President Michael Ribot, attended the Review of Medicines and Medical Devices Regulation First Report Stakeholder Forums on the 5th and 6th of August 2015. There were five key themes to emerge from both forums, and the AHMADA team will continue to liaise with the Department of Health through direct contact with senior staff, and where necessary, the appropriate ministers. We will also continue to be involved in the feedback process through further stakeholder forums.

The full “Review of Medicines and Medical Devices Regulation” report, as well as “Participant Information” packs and the “Summary of Feedback” documents are available to view by clicking each of the links below:



Any feedback from our members is welcomed. Contact us at for further information.



get link Australian Manufacturing Online Magazine

AHMADA has been featured in an article from Australian Manufacturing’s online magazine in relation to the Patent Box Tax Policy, which we would like to see introduced here in Australia.

Our President Dr Mal Eutick, emphasises that the implementation of a special tax regime for Intellectual Property revenues – a concept first introduced by the Irish in 2000 – would incentivise local health manufacturers to patent and retain their valuable IP and manufacturing within Australia, with its flow-on benefits to the local economy.

simulatore utilizzo derivati Article:  AHMADA calls for introduction of “Patent Box” tax policy

Australian Manufacturing Magazine

Link to article:


June 2015

Annual General Meeting 25th of June 2015

agmpic1 agmpic2

We would like to thank all of our Members and guests for attending our AGM on the 25th of June this year.

An important item on our agenda was the official change of name for our association. We are now the Australian Health Manufacturers and Development Association with a unanimous vote decided by our members. This name change signifies our focus to supporting local Australian pharmaceutical and medical device manufacturers, and developing a niche approach to working with government to achieve significant change locally.

Our Vice President for 2015/16 has also been announced and we would like to congratulate Michael Ribot from Global Orthopaedic Technology in fulfilling this role for AHMADA. Mr Ribot has over 30 years of experience in the Orthopaedic market and has worked closely with Australian surgeons in developing Global’s implant and instrument portfolio. We welcome his vast knowledge and experience to further AHMADA’s objectives.

Voting Conducted at the AGM 2015

Voting was conducted at our Annual General Meeting on June 25th 2015 and all members voted unanimously on all five areas. We would like to thank our members for attending and voting.

Our voting results are hereby as follows:

  • Change of Name from: Australasian Health Manufacturers and Development Association to Australian Health Manufacturers and Development Association (accepted by unanimous vote).
  • Change of Slogan from: “Innovating a way forward”, to “Innovating a way forward for Australia” (accepted by unanimous vote).
  • Vote on Vice Presidency: Mr Mike Ribot from Global Orthopaedic Technology (accepted by unanimous vote).
  • Vote on retaining our President for another term (accepted by unanimous vote).
  • Committee and Public Officer were accepted by unanimous vote.



Annual General Meeting Announcement

We are officially announcing our first AGM to be held on June 25th 2015 in Melbourne for our members. Members will receive details on the venue and agenda shortly.



TGA Review of Medicines and Medical Devices Discussion Paper Submission

AHMADA would like to thank all its members for their submissions regarding the TGA review of Medicines and Medical Devices Discussion Paper. We have received confirmation that our collective submission has been accepted, and we will keep our members updated on any future correspondence.

Keep updated with our Twitter Page at


 January 2015

AHMADA in the Media

Australian Manufacturing Online Magazine

AHMADA has been recognised in a written piece by Australia’s leading online magazine, Australian Manufacturing, reflecting our support of the Industry Skills Fund, due for commencement in early 2015.

Our President emphasises the importance of the fund for our members:

“AHMADA welcomes the establishment of the Fund as it clearly aligns with one of our key priorities for Members — that local research and development (R&D) must be capitalised into innovative new products”.

“Our members, developing and manufacturing local research across the health, pharmaceutical and medical technology sectors, are competing with the much-larger multi-nationals and are focused on local research and investment in skill development and employment for local scientists. The Government’s commitment to assisting industry and innovation through the establishment of the Fund will further support our Members with the opportunity to compete locally and in the highly competitive global marketplace.”

Find the article here